The market for cell and gene therapies continues to accelerate and presents unique supply chain challenges. Unlike traditional pharmaceutical products that are manufactured and delivered at scale, cell and gene therapies are unique to a specific patient. And since cell and gene therapies are generally a treatment of last resort, patients are often very sick. One delay or temperature excursion could render a therapy obsolete and mean life or death for a patient.
In a recent article in Pharmaceutical Commerce, Vince Paolizzi, Director of NanoCool Sales at Peli BioThermal, shares background on the cell and gene therapy market and discusses the nuances of temperature control for these therapies. View the full article on Pharmaceutical Commerce’s website.
